Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.

T-cells attacking cancer_1200x675
Amgen's BiTE molecules recruit T-cells to targeted tumors. • Source: Shutterstock

Amgen Inc. is starting to reach key value-inflection points in its early-stage cancer drug pipeline as it attempts to develop a portfolio of innovative, differentiated therapies that will be effective on their own and build on the promise of immuno-oncology agents, such as PD-1 inhibitors.

The company has a well-established portfolio of blockbuster supportive care therapies, including the anemia treatment Epogen (epoetin alfa), neutropenia therapies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category